 WALTHAM, Mass., Aug. 10, 2021 GLOBE NEWSWIRE -- EyeGate Pharmaceuticals, Inc. NASDAQ: EYEG EyeGate or the Company, a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale, in a registered direct offering priced at-the-marked under Nasdaq rules, of 4,668,844 shares of its common stock at a purchase price of 2.3025 per share for gross proceeds of approximately 10.75 million, before deducting placement agents fees and other offering expenses. The Company has also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 2,334,422 shares of common stock. The closing of the offering is expected to occur on or about August 11, 2021, subject to the satisfaction of customary closing conditions. 